AsymBio, a leading China-based biologics Contract Development and Manufacturing Organization (CDMO), is excited to announce that it has successfully passed the European Union Qualified Person (QP) Audit. This achievement underscores AsymBios adherence to stringent guidelines and regulations by the E...

AsymBio, a leading biologics Contract Development and Manufacturing Organization (CDMO), took center stage at the Antibody Engineering and Brian Dwyer, Ph.D, Director of Business Development, engaged with industry leaders and experts throughout the conference.AsymBio highlighted its deep expertise ...

Under the leadership of the CTO, Dr. Kai Gao, the AsymBios team embarked on a two-day team building at Mount Huangshan. This event provided an opportunity for the team to relax, rejuvenate, and build lasting connections between team members.

On April 4, 2023, AsymBio held its 2023 annual meeting in a combination of both online and offline formats. The meeting reaffirmed and conveyed the development strategies and plans for AsymBio in 2023. The company will rally around the guideline of s development direction and goals in 2023 was estab...

Asymchem Group (Stock Codes: 002821.SZ, 6821.HK, hereinafter referred to as s strengths and deepening their cooperation. This partnership aims to create greater economic and social benefits, continually improve unmet clinical needs, and join hands to benefit patients worldwide.

Asymchem Group (Stock Codes: 002821.SZ/6821.HK, hereinafter referred to as s rich project experience and professional expertise in the payload-linker field. It offers a one-stop CMC service for ADC drugs, including antibody intermediate and bulk conjugation, as well as formulation filling. This serv...